Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31127222 | 1.00 | IDH1 (0.35) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL19686731 | 0.85 | IDH1 (0.33) | IDH1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21166244 | 0.78 | IDH1 (0.37) | IDH1 | |
| SCHEMBL31127166 | 0.76 | IDH1 (0.41) | IDH1 | |
| SCHEMBL21143856 | 0.76 | IDH1 (0.41) | IDH1 | |
| SCHEMBL19687330 | 0.74 | IDH1 (0.47) | IDH1 | |
| SCHEMBL31127224 | 0.73 | KCNN2 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL19686322 | 0.73 | KCNN2 (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL31127355 | 0.72 | GABRA1 (0.35) | IDH1GABRA1 | |
| SCHEMBL19686410 | 0.72 | GABRA1 (0.35) | IDH1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885GABRA1 325/4885GABRG2 436/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885GABRA1 325/4885GABRG2 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.